


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) Compounds of the general formula I



in which

$R^1$  is H or A,

$R^{2'}$ ,  $R^{2''}$ ,  $R^{2'''}$  are each, independently of one another, H, A, OH, OCH<sub>3</sub>, OCF<sub>3</sub>, Hal, CN, COOR<sup>1</sup>, CONR<sup>1</sup> or NO<sub>2</sub>,

$R^3$  is A, Ar or A-Ar,

$R^4$  is H or A,

A is unbranched or branched alkyl having 1-10 carbon atoms, in which one or two CH<sub>2</sub> groups may be replaced by O or S atoms and/or by -CH=CH- groups and/or 1-7 H atoms may also be replaced by F,

Ar is phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR<sup>4</sup>, N(R<sup>4</sup>)<sub>2</sub>, NO<sub>2</sub>, CN, COOR<sup>4</sup>, CON(R<sup>4</sup>)<sub>2</sub>, NR<sup>4</sup>COA, NR<sup>4</sup>CON(R<sup>4</sup>)<sub>2</sub>, NR<sup>4</sup>SO<sub>2</sub>A, COR<sup>4</sup>, SO<sub>2</sub>N(R<sup>4</sup>)<sub>2</sub> or SO<sub>2</sub>A,

A-Ar is arylalkyl, where A and Ar have one of the above-mentioned meanings,

Hal is F, Cl, Br or I, and

n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10,

and solvates, stereoisomers and pharmaceutically usable derivatives, thereof, including mixtures thereof in all ratios.


2. (Original) Compounds according to Claim 1, in which

$R^1$  is hydrogen,


and solvates, stereoisomers and pharmaceutically usable derivatives thereof, including mixtures thereof in all ratios.

3. (Currently Amended) Compounds according to Claim 1 ~~or 2~~, in which  
 $R^{2'}$ ,  $R^{2''}$ ,  $R^{2'''}$  are hydrogen,  
and solvates, stereoisomers and pharmaceutically usable derivatives thereof,  
including mixtures thereof in all ratios.
  
4. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-3~~, in which  $R^3$  is n-propyl, i-propyl, n-butyl, 2,2,2-trifluoroethyl, phenyl, benzyl or 2-nitrophenylmethyl,  
and solvates, stereoisomers and pharmaceutically usable derivatives thereof,  
including mixtures thereof in all ratios.
  
5. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-4~~, in which  
n is 1,  
and solvates, stereoisomers and pharmaceutically usable derivatives thereof,  
including mixtures thereof in all ratios.
  
6. (Original) Compounds according to Claim 1 selected from the group consisting of  
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-C-phenylmethanesulfonamide,  
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-C-[2-nitrophenyl]methanesulfonamide,  
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]benzenesulfonamide,  
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-2-propanesulfonamide,  
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-1-butanesulfonamide,  
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-1-propanesulfonamide,  
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-1-2,2,2-trifluoroethanesulfonamide,  
and solvates, stereoisomers and pharmaceutically usable derivatives thereof,  
including mixtures thereof in all ratios.


7. (Currently Amended) Process for the preparation of compounds of the formula I according to claim 1 ~~Claims 1-6~~ and pharmaceutically usable derivatives, solvates and stereoisomers thereof, characterised in that
- a) a compound of the formula V




in which R is a nucleophilic leaving group usually employed for nucleophilic substitutions on aromatic compounds, is reacted with a compound of the formula VI



in which R<sup>2'</sup>, R<sup>2''</sup>, R<sup>2'''</sup> and n are as defined in Claim 1, giving a compound of the formula IV



- b) the resultant phenoxy-piperidine of the formula IV is converted by hydrogenation and optionally alkylation into a compound of the formula II



in which R<sup>1</sup> is as defined in Claim 1, which is then

- c) reacted further with a compound of the formula III

in which R3 is as defined in Claim 1, and L is a nucleophilic leaving group known per se, giving a compound of the formula I,  
and optionally a protecting group is subsequently cleaved off,  
and/or a base or acid of the formula I is converted into one of its salts.


8. (Currently Amended) Compounds of the formula I and pharmaceutically usable derivatives, solvates and stereoisomers thereof according to claim 1 ~~one or more of Claims 1 to 6~~ as effectors of the nicotinic acetylcholine receptor.
9. (Currently Amended) Compounds of the formula I and pharmaceutically usable derivatives, solvates and stereoisomers thereof according to claim 1 ~~one or more of Claims 1 to 6~~ as effectors of the muscarinic acetylcholine receptor.
10. (Currently Amended) Compounds of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, according to claim 1 ~~one or more of Claims 1 to 6~~ as medicaments.
11. (Currently Amended) Medicaments comprising at least one compound of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, according to claim 1 ~~one or more of Claims 1 to 6~~, and optionally excipients and/or adjuvants.
12. (Currently Amended) Medicaments comprising at least one compound of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, according to ~~one or more of Claims 1 to 6~~, and at least one further medicament active ingredient.

13. (Currently Amended) Use of compounds according to claim 1 ~~one or more of Claims 1 to 6~~ and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the prophylaxis or treatment of diseases in which the binding of one or more active ingredients present in the said medicament to nicotinic and/or muscarinic acetylcholine receptors leads to an improvement in the clinical picture.
14. (Currently Amended) Use of compounds according to claim 1 ~~one or more of Claims 1 to 6~~ and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the prophylaxis or treatment of schizophrenia, depression, anxiety states, dementia, Alzheimer's disease, Lewy bodies dementia, neurodegenerative diseases, Parkinson's disease, Huntington's disease, Tourette's syndrome, learning and memory impairments, age-related memory impairment, amelioration of withdrawal symptoms in nicotine dependence, strokes or brain damage by toxic compounds.
15. (Currently Amended) Pharmaceutical composition, characterised by a content of at least one compound of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, according to claim 1 ~~one or more of Claims 1 to 6~~.
16. (Currently Amended) Process for the preparation of a pharmaceutical compositions according to Claim 15, characterised in that comprising at least one compound of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, according to claim 1 ~~one or more of Claims 1 to 6~~ is converted comprising converting said composition into a suitable dosage form together with at least one solid, liquid or semi-liquid excipient or adjuvant.

17. (Currently Amended) Set (kit) consisting of separate packs of
- (a) an effective amount of a compound of the formula I according to ~~one or more of Claims 1 to 6~~ and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and
  - (b) an effective amount of a further medicament active ingredient.


18. (Currently Amended) Use of compounds of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, according to claim 1 ~~one or more of Claims 1 to 6~~, for the preparation of a medicament for the prophylaxis or treatment of schizophrenia, depression, anxiety states, dementia, Alzheimer's disease, Lewy bodies dementia, neurodegenerative diseases, Parkinson's disease, Huntington's disease, Tourette's syndrome, learning and memory impairments, age-related memory impairment, amelioration of withdrawal symptoms in nicotine dependence, strokes or brain damage by toxic compounds, in combination with at least one further medicament active ingredient.

19. (Original) Intermediate compounds of the formula IV



in which  $R^{2'}$ ,  $R^{2''}$ ,  $R^{2'''}$  and  $n$  are as defined in Claim 1, and salts thereof.

20. (Original) Intermediate compounds of the formula VI



in which  $R^{2'}$ ,  $R^{2''}$ ,  $R^{2'''}$  and  $n$  are as defined in Claim 1,  
and salts thereof.